RecruitingPhase 1/2

The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia

Pakistan60 participantsStarted 2025-05

Plain-language summary

The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone. The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone. The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.

Who can participate

Age range1 Month – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1 month to 12 years * Both genders * Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition Exclusion Criteria: * Hospitalized within 14 days prior to the study * Known TB exposure * Active varicella or herpes simplex infection * Allergy to the study medication * Currently taking melatonin * Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care * Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption * Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric

What they're measuring

Length of hospital stay

Timeframe: 14 days

Trial details

NCT IDNCT06949904

SponsorMian Muhammad Hassan Ahmed

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Pneumonia Childhood trials